Bayer

Bayer

Verified
Global enterprise with core competencies in the Life Science fields of health care and agriculture. Learn more

Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$64.6b (Public information from Jul 2024)
Company register number 00218826
Leverkusen Nordrhein-Westfalen (HQ)
Corporate Venture Fund: G4A, Leaps by Bayer

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2020202120222023202420252026
Revenues41.4b44.1b50.7b47.6b47.1b47.9b48.7b
% growth(5 %)6 %15 %(6 %)(1 %)2 %2 %
EBITDA10.3b10.0b12.8b11.2b10.2b10.9b11.0b
% EBITDA margin25 %23 %25 %23 %22 %23 %23 %
Profit(10.5b)1.0b4.2b(2.9b)2.1b3.2b3.4b
% profit margin(25 %)2 %8 %(6 %)4 %7 %7 %
EV / revenue2.0x1.8x1.6x0.7x1.3x1.2x1.1x
EV / EBITDA8.2x7.9x6.2x3.0x5.9x5.2x4.8x
R&D budget7.1b5.4b6.6b5.4b---
R&D % of revenue17 %12 %13 %11 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
*

$12.0m

Grant
Total Funding$12.0m

Recent News about Bayer

Edit
More about Bayerinfo icon
Edit

Bayer Pharmaceuticals is a global leader in the healthcare and agriculture sectors, with a strong focus on innovation and research. The company operates in the pharmaceutical market, primarily targeting diseases and health conditions that require advanced medical treatments. Bayer's clientele includes healthcare providers, hospitals, and patients who benefit from their extensive range of prescription medications and therapies.

Bayer operates in a highly competitive market, focusing on areas such as oncology (cancer treatment), cardiology (heart health), and women's health. The company is committed to developing new drugs and therapies through rigorous clinical trials and research. For instance, Bayer is actively involved in the development of rivaroxaban, a medication aimed at preventing blood clots, and finerenone, which is being tested for its effectiveness in treating certain heart conditions.

The business model of Bayer Pharmaceuticals revolves around the development, production, and sale of prescription drugs. They invest heavily in research and development (R&D) to bring new drugs to market, which involves a lengthy process of clinical trials to ensure safety and efficacy. Once a drug is approved, Bayer generates revenue through the sale of these medications to healthcare providers and pharmacies, who then distribute them to patients.

Bayer also collaborates with other biotech firms and research institutions to expand its pipeline of potential new treatments. For example, their partnership with Vividion Therapeutics aims to leverage cutting-edge scientific research to discover new drug candidates.

In summary, Bayer Pharmaceuticals is a well-established player in the healthcare industry, known for its commitment to innovation and improving patient outcomes through advanced medical treatments.

Keywords: Pharmaceuticals, Healthcare, Innovation, Research, Oncology, Cardiology, Clinical Trials, Prescription Drugs, Biotechnology, Partnerships.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
Blackford Analysis
ACQUISITION by Bayer Jan 2023
Zoner.ag
ACQUISITION by Bayer Feb 2016
Algeta
ACQUISITION by Bayer Dec 2013
AgraQuest
ACQUISITION by Bayer Jul 2012
DIREVO Biotech AG
ACQUISITION by Bayer Sep 2008
View 169 more